Literature DB >> 10766197

BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.

M W Deininger1, S Vieira, R Mendiola, B Schultheis, J M Goldman, J V Melo.   

Abstract

The BCR-ABL chimeric protein is thought to play a central role in the pathogenesis of Philadelphia (Ph) chromosome-positive leukemias, notably chronic myeloid leukemia (CML). There is compelling evidence that malignant transformation by BCR-ABL is critically dependent on its protein tyrosine kinase (PTK) activity. As a result, multiple signaling pathways are activated in a kinase-dependent manner, and thus the activation of such pathways may affect the expression of genes that confer the malignant phenotype. In this study, we used differential display to investigate the alterations of gene expression in BV173, a CML cell line derived from lymphoid blast crisis, after exposure to ST1571, which selectively inhibits ABL PTK activity. We show that the expression of a set of 12 genes is correlated with the kinase activity and that the profile of these genes reflects mechanisms implicated in the pathogenesis of CML. Several of the genes show a consistent pattern of altered regulation in all Ph-positive lymphoid cell lines, whereas others appear to be unique to BV173 cells. We conclude that BCR-ABL PTK activity drives the expression of specific target genes that contribute to the malignant transformation of Ph-positive cells. The identification of downstream molecules with a consistent regulation pattern may provide suitable targets for therapeutic intervention in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766197

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.

Authors:  B H Srinivas; T Roshni Paul; Shantveer G Uppin; Megha S Uppin; Rachel T Jacob; D Raghunadharao
Journal:  Indian J Hematol Blood Transfus       Date:  2012-01-31       Impact factor: 0.900

2.  Effects of STI571 and p27 gene clone on proliferation and apoptosis of K562 cells.

Authors:  Wei Wang; Li-Bo Yao; Xin-Ping Liu; Qi Feng; Zhen-Chuan Shang; Yun-Xin Cao; Bing-Zhong Sun
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 3.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 4.  Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

Authors:  Kush Patel; Zainab So Ahmed; Xuemei Huang; Qianqian Yang; Elmira Ekinci; Christine M Neslund-Dudas; Bharati Mitra; Fawzy Aem Elnady; Young-Hoon Ahn; Huanjie Yang; Jinbao Liu; Qing Ping Dou
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

5.  Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.

Authors:  Alexandra Mazharian; Cedric Ghevaert; Lin Zhang; Steffen Massberg; Steve P Watson
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

6.  Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.

Authors:  Qing Huang; Yan Yang; Xiaoqing Li; Shiang Huang
Journal:  Tumour Biol       Date:  2011-09-03

Review 7.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

8.  Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.

Authors:  Alina Felicia Nica; Chun Chui Tsao; Julie C Watt; Tilahun Jiffar; Svitlana Kurinna; Paul Jurasz; Marina Konopleva; Michael Andreeff; Marek W Radomski; Peter P Ruvolo
Journal:  Cell Cycle       Date:  2008-11-02       Impact factor: 4.534

9.  Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.

Authors:  Ana Paula Zambuzi Cardoso Marsola; Belinda Pinto Simões; Leonardo Carvalho Palma; Maria Gabriela Berzoti-Coelho; Sandra Mara Burin; Fabíola Attié de Castro
Journal:  Med Oncol       Date:  2018-01-31       Impact factor: 3.064

Review 10.  Deactylase inhibition in myeloproliferative neoplasms.

Authors:  Sridurga Mithraprabhu; George Grigoriadis; Tiffany Khong; Andrew Spencer
Journal:  Invest New Drugs       Date:  2010-12-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.